This clinical photograph depicts a healthcare setting in a resource-limited environment, specifically documenting the administration of intravenous (IV) therapy for an obstetric emergency. A female patient, identified by the context as having pre-eclampsia, is lying supine in a hospital bed. A healthcare professional in a white clinical coat is actively managing the IV setup, holding a clear plastic infusion bag (containing magnesium sulphate) elevated above the patient to facilitate gravity-fed flow. The IV tubing is visible, extending from the bag to an insertion point on the patient's arm. The image illustrates critical maternal health interventions and the clinical management of hypertensive disorders of pregnancy. The surrounding individuals and their attire, including headscarves and traditional garments, provide cultural context for the clinical setting in Afghanistan. This visual serves as an educational resource for global health, emergency obstetric care, and the practical application of magnesium sulphate protocols in preventing eclamptic seizures.

Summary : This flowchart outlines the management of fetuses in pregnancies complicated by suspected or documented inherited arrhythmia syndrome (IAS), with a focus on long QT syndrome (LQTS) and fetal arrhythmias. It details recommended steps, decision points, and treatments, using color codes to indicate the class of recommendation (COR). flowchart: # Nodes : • Start (rectangle): "Pregnancy complicated by suspected or documented IAS*" • Rectangle: "Fetal echocardiography (COR 1)" • Rectangle: "Assess fetal heart rate at each prenatal visit and compare against gestation-specific normative values (COR 1)" • Rectangle: "Limit medications that could lengthen the QTc or trigger arrhythmias in fetus (COR 1)" • Rectangle (yellow): "fMCG, if available (COR 2a)" • Diamond: "Fetal arrhythmia suggestive of IAS*" • Rectangle: "Referral to a cardio-obstetrics team (COR 1)" • Rectangle: "Fetal arrhythmia associated with exposure to QT-prolonging medications" • Rectangle (yellow): "Evaluate for nutritional deficiency states, or concealed maternal or fetal diseases associated with QT prolongation (COR 2a)" • Rectangle: "Prenatal and postnatal persistent fetal bradycardia" • Rectangle (yellow): "Postnatal ECG and referral to a pediatric cardiologist or electrophysiologist for further clinical evaluation and genetic testing, as indicated, to exclude IAS (COR 2a)" • Rectangle: "Fetal TdP" • Rectangle: "Maternal intravenous loading dose of magnesium sulfate followed by continuous infusion as first-line therapy (COR 1)" • Rectangle (yellow): "Maternal treatment with lidocaine or a beta-blocker (preferably propranolol) (COR 2a)" • Rectangle: "Associated with LQTS" • Rectangle (red): "Sotalol, procainamide, and amiodarone should not be administered (COR 3: Harm)" # Connectors : • Downward arrows connect each step in sequence. • After "Fetal echocardiography", arrows lead to "Assess fetal heart rate..." and then to "Limit medications...". • From "Limit medications...", arrow leads to "fMCG, if available". • From "fMCG, if available", arrow leads to "Fetal arrhythmia suggestive of IAS*". • From "Fetal arrhythmia suggestive of IAS*", arrow leads to "Referral to a cardio-obstetrics team". • From "Referral to a cardio-obstetrics team", three branches: – Left: "Fetal arrhythmia associated with exposure to QT-prolonging medications" → "Evaluate for nutritional deficiency states..." – Middle: "Prenatal and postnatal persistent fetal bradycardia" → "Postnatal ECG and referral..." – Right: "Fetal TdP" → "Maternal intravenous loading dose..." → "Maternal treatment with lidocaine or a beta-blocker..." → "Associated with LQTS" → "Sotalol, procainamide, and amiodarone should not be administered" • Some steps loop back to earlier steps (e.g., assessment at each prenatal visit). # Layout : • Vertical flow from top to bottom, with a major split into three branches after referral to cardio-obstetrics team. • Color coding: Green (COR 1: strong recommendation), Yellow (COR 2a: moderate recommendation), Red (COR 3: harm). • Decision diamond for arrhythmia presence. • Merges and branches for different arrhythmia scenarios. # Analysis : • The flowchart emphasizes early and repeated fetal heart assessment, medication management, and specialist referral. • It provides clear pathways for different arrhythmia findings: exposure to QT-prolonging drugs, persistent bradycardia, and fetal TdP. • Strong recommendations (green) are given for initial steps and magnesium sulfate therapy; moderate recommendations (yellow) for additional diagnostics and treatments; and explicit harm warnings (red) for certain drugs in LQTS. • The structure supports rapid identification and tailored management of fetal arrhythmias, with escalation to advanced therapies and genetic evaluation as needed.

Recommendations for management of inherited arrhythmia syndromes in the fetus, specifically long QT syndrome <table><thead><tr><th>COR</th><th>LOE</th><th>Recommendations</th><th>References</th></tr></thead><tbody><tr><td>1</td><td>B-NR</td><td>1. In pregnancies complicated by suspected or documented IAS-related fetal arrhythmias, complete fetal echocardiography is recommended to better evaluate heart anatomy, ventricular function, and arrhythmia mechanisms.</td><td>407,426,435,442,471</td></tr><tr><td>1</td><td>B-NR</td><td>2. Fetuses with arrhythmias potentially suggestive of IAS should be referred to a cardio-obstetrics team with expertise in IAS management.</td><td>154,426,430,435,437,472</td></tr><tr><td>1</td><td>B-NR</td><td>3. In pregnancies complicated by suspected or documented IAS, the fetal heart rate should be assessed initially as a baseline and at each prenatal visit and compared against gestation-specific normative values.</td><td>153,407,429,435,471</td></tr><tr><td>1</td><td>B-NR</td><td>4. In fetuses with TdP, a maternal intravenous loading dose of magnesium sulfate followed by continuous infusion should be administered as first-line therapy at all stages of pregnancy before considering urgent delivery.</td><td>154,426,430</td></tr><tr><td>1</td><td>C-LD</td><td>5. In pregnancies complicated by suspected or documented maternal or fetal IAS, limiting medications that could potentially lengthen the QTc or trigger arrhythmias in the fetus is recommended.</td><td>154,426,434,472</td></tr><tr><td>2a</td><td>B-NR</td><td>6. In pregnancies complicated by suspected or documented fetal IAS, fMCG can be beneficial, if available, to identify affected fetuses and IAS-related repolarization abnormalities, and to better assess the severity of the IAS-related arrhythmias.</td><td>154,426,430,431,472</td></tr><tr><td>2a</td><td>B-NR</td><td>7. In fetuses with TdP despite magnesium administration, maternal treatment with lidocaine or with a beta-blocker (preferably propranolol) is reasonable at all stages of pregnancy before considering urgent delivery.</td><td>154,426,430</td></tr><tr><td>2a</td><td>C-LD</td><td>8. In fetuses with prenatal and postnatal persistent bradycardia, it is reasonable to obtain a postnatal ECG and referral to a pediatric cardiologist or electrophysiologist for further clinical evaluation and genetic testing as indicated to exclude IAS.</td><td>154,435</td></tr><tr><td>2a</td><td>C-LD</td><td>9. In fetuses manifesting arrhythmias associated with exposure to QT-prolonging medications, evaluation for maternal nutritional deficiency or concealed maternal or fetal diseases associated with QT prolongation is reasonable.</td><td>154,426,429,435,471</td></tr><tr><td>3: Harm</td><td>C-LD</td><td>10. In fetuses with TdP or polymorphic VT associated with potential or documented LQTS, sotalol, procainamide, and amiodarone should not be administered because they can further lengthen QTc and exacerbate arrhythmias.</td><td>154,426,435</td></tr></tbody></table>

This composite image illustrates the microscopic and macroscopic characteristics of magnesium sulfate (MgSO4)-induced fibrinogen fibrillogenesis, a process relevant to understanding non-enzymatic protein aggregation and blood coagulation research. The image features two scanning electron microscopy (SEM) micrographs and an inset clinical photograph. The SEM images, shown at 1 μm and 2 μm scales, reveal a dense, interconnected network of long, fibrous protein strands. These fibers exhibit a random orientation and form a complex mesh-like architecture with visible interstitial pores. Morphologically, the fibers appear relatively thick and irregular, characteristic of 'pseudo-fibrin' formation where fibrinogen self-assembles without thrombin catalysis. The inset photograph shows the macroscopic result of this process: a homogeneous, turbid, milky-white gel within a transparent glass vial. The opacity of the solution confirms the light-scattering properties of the dense protein fiber network. This visual material is primarily used in hematology and biochemistry to study alternative pathways of fibrin formation and the influence of ionic environments on protein structural dynamics.